We quantitated MCPyV-specific T cells in the peripheral blood throughout the therapeutic course to understand how anti-PD-1 therapy affects the kinetics of tumor-specific CD8+ T cell expansion or contraction. The gene discussed is CD8A; the disease is neoplasm.